Search results
Results from the WOW.Com Content Network
Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists [2] are a group of medications that disrupt the movement of calcium (Ca 2+ ) through calcium channels . [ 3 ] Calcium channel blockers are used as antihypertensive drugs , i.e., as medications to decrease blood pressure in patients with hypertension .
ATC code C08 Calcium channel blockers is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup C08 is part of the anatomical group C Cardiovascular system ...
Class IV agents are slow non-dihydropyridine calcium channel blockers. They decrease conduction through the AV node, and shorten phase two (the plateau) of the cardiac action potential. They thus reduce the contractility of the heart, so may be inappropriate in heart failure.
This list may not reflect recent changes. ... Dihydropyridine calcium channel blockers; Diltiazem; Diproteverine; ... a non-profit organization.
The 8th Joint National Committee (JNC-8) recommends calcium channel blockers to be a first-line treatment either as monotherapy or in combination with thiazide-type diuretics, ACEis, or ARBs for all patients regardless of age or race. [7] The ratio of CCBs' anti-proteinuria effect, non-dihydropyridine to dihydropyridine was 30 to −2. [13]
It is in the non–dihydropyridine calcium channel blocker family of medications. [9] Verapamil was approved for medical use in the United States in 1981. [9] [13] It is on the World Health Organization's List of Essential Medicines. [14] Verapamil is available as a generic medication. [9] Long acting formulations exist. [12]
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Age ≥55 or black: CCB ADA 2018 [11] Diabetes Diabetes with CVD risk <140/90 <130/80 ACEI/ARB, thiazide-like diuretic, and/or dihydropyridine CCB ESC / ESH 2018 [12] General age <65 General age ≥65 <130/80 <140/80 Thiazide-type diuretic, ACEI/ARB, and/or CCB CAD: add beta-blocker Resistant hypertension: add spironolactone ACC / AHA 2017 [13 ...